COMMUNIQUÉS West-GlobeNewswire

Axovia Therapeutics Announces Presentation of Preclinical Data Supporting Lead Program AXV-101 for Treatment of Blindness Associated with BBS1 Mutations at ASGCT
10/05/2024
- Data show that AXV-101 halts photoreceptor and outer nuclear retinal layer (ONL) degeneration in a dose-dependent manner - - Company to initiate clinical studies in 1H 2025 to treat blindness and progress AXV-101 [...]
Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024
10/05/2024
Management to host conference call and webcast at 8:30am ET PITTSBURGH, May 10, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial [...]
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
10/05/2024
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 [...]
Apertura Gene Therapy Showcases Advancements in Capsid Engineering Platform in Presentations at ASGCT Annual Meeting
10/05/2024
– Significant advancements in engineering neutralizing antibody (NAb) evasion properties into receptor-targeted capsids, including novel TfR1-binding capsids, demonstrate increased opportunities to treat AAV [...]
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
10/05/2024
Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide a perspective on CKD [...]
Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
10/05/2024
Poster presentation details screening approach allowing selection of candidate molecules applicable to dry eye disease and chronic ocular pain, with potential to identify therapeutic candidates with novel mechanisms of [...]
Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
10/05/2024
-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real- [...]
Humacyte First Quarter 2024 Financial Results and Business Update
10/05/2024
-Biologics License Application (BLA) for HAV™ Accepted by FDA- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43 million in net proceeds from [...]
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
10/05/2024
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) Preclinical data demonstrates [...]
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
10/05/2024
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a [...]
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance
10/05/2024
Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7% , net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82 Delivered record [...]
Le TAR-200 en monothérapie montre un taux de réponse complète supérieur à 80 pour cent chez les patients atteints d’un cancer de la vessie n’infiltrant pas le muscle à haut risque
10/05/2024
Les nouvelles données issues de l’étude de Phase IIb SunRISe-1 montrent l’obtention rapide d’une réponse complète (RC), 98 pour cent des patients ayant présenté une RC dans les 12 semaines 1 Le TAR-200 permet d’obtenir [...]
CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients
10/05/2024
Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE [...]
Tome Biosciences Presented Data on its Programmable Genomic Integration Technologies at ASGCT
10/05/2024
Achieved therapeutically-relevant targeted gene integration and functional protein expression in vivo in non-human primates Demonstrated efficient multiplex editing and integration of large DNA sequences with functional [...]
Tessera Therapeutics Presents New Preclinical Data Highlighting Advancements Across Its Portfolio Programs and Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting
10/05/2024
Gene Writing™ platform demonstrates highly efficient in vivo correction of mutation responsible for alpha-1 antitrypsin deficiency (AATD) to wild-type Combination of proprietary lipid nanoparticle (LNP) delivery to long [...]
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
10/05/2024
Research includes the first-ever application of AsCas12a in vivo , optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Company’s in vivo gene editing medicines pipeline [...]
IBA : 2024 AGM - Convening Notice
10/05/2024
Cher Actionnaire, Nous avons l’honneur de vous convoquer à l’Assemblée Générale Ordinaire (l’« AGO » ) des actionnaires d’IBA qui se tiendra le mercredi 12 juin 2024 à 10h00 , pour délibérer sur l’ordre du jour détaillé [...]
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
10/05/2024
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based [...]
Communiqué de presse : Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19
10/05/2024
Sanofi et Novavax concluent un accord de licence co-exclusif pour la co-commercialisation d’un vaccin COVID-19 et le développement de vaccins combinés grippe - COVID-19 L’accord, qui combinera la puissance commerciale [...]

Pages